Overview
Development Programs
Differentiated, once-daily oral PDE4 inhibitor prodrug designed for targeted activation in the gastrointestinal tract, initially focused on addressing unmet need in IBD.
❯ More
Your tooltip content goes here
PALI-2108 (PDE4 Inhibitor Prodrug, Once Daily)
Indication
Ulcerative Colitis (UC)
Status
Phase 2
Highlights
Completed and reported topline data for Ph1
IND and Ph2 expected to commence in 2026
Indication
Crohn’s Disease (CD)
Status
Phase 2
Highlights
Completed and reported topline data for Ph1
IND and Ph2 expected to commence in 2026/27
(finalizing study design)
PDE4 Platform
Sign Up For Alerts